MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock.
Global life sciences and nutraceutical ingredients developer Suanfarma has acquired Monteloeder (Madrid, Spain), a company with 25 years of experience creating clinically studied branded botanical ingredients for dietary supplements, foods, and beverages.
To be able to copy & paste content to share with others please contact us at subscriptions@peimedia.com to upgrade your subscription to the appropriate licence